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Exploring new treatments for
chronic kidney disease
To the Editor: We read with interest the excellent review
by Turner et al.1 of both established and non-traditional
treatment options for slowing progression of chronic kidney
disease. The authors are to be commended for their
consideration of novel applications of established therapies
and metabolic targets not traditionally associated with
treatments to slow disease progression.
We wish to point out an omission in this report of a
therapy with great promise. Pentoxifylline has been studied
prospectively in more than 1000 patients enrolled in 19
clinical trials to date, with consistently positive results across
disparate populations, without apparent toxicity, and with an
excellent adverse-effect proﬁle.
Pentoxifylline is a non-speciﬁc phosphodiesterase inhibitor
with renal anti-inﬂammatory, antioxidant, and anti-ﬁbrotic
activity.2 The drug targets a distinctly different pathophysio-
logical mechanism of chronic kidney disease progression than
that of angiotensin-converting enzyme inhibitors and angio-
tensin receptor blockers.2 Pentoxifylline reduces proteinuria
and preserves kidney function among patients with diabetic
and non-diabetic chronic kidney disease, with or without
concomitant inhibition of the renin–angiotensin axis, an
important consideration given that a substantial proportion
of diabetic patients either cannot tolerate or develop
tachyphylaxis to such therapies.3,4
Health-care resources in the United States and globally will
become increasingly constrained in the years to come; it is
therefore essential that the nephrology community continues
to explore new applications of existing therapies with
demonstrated efﬁcacy for slowing the progression of a disease
that may impact X10% of the world’s adult population. We
would be foolish to do otherwise.
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The Authors Reply: We appreciate the letter from Perkins and
Yuan1 who point out that we omitted a discussion about
pentoxifylline in our recent review on treatment options for
chronic kidney disease (CKD).2 One of the challenges in writing
this piece was selecting which novel therapies should be included
in our relatively abridged discussion on this topic. This speaks to
the large number of medical therapies for CKD that have been
investigated in recent years, and the fact that very few have been
adopted into standard practice. We employed the following
criteria as a guide for selecting which agents to include in our
discussion: (1) a plausible mechanism of action supported by in
vitro and animal studies; (2) evidence of efﬁcacy and safety in
human studies, preferably randomized placebo-controlled trials;
and (3) the ever important buzz factor (admittedly a highly
subjective indicator). We concede that pentoxifylline meets
criteria 1 and 2. In terms of criterion 3, we may be able to better
answer this when the results of the PREDIAN study are known.3
With that said, it is important to acknowledge that Perkins and
Yuan’s point is well taken regarding the merits of pentoxifylline
as an effective agent for slowing CKD. This is a dynamic area of
research and in a few years, a similar review of therapies may
look very different depending on the outcomes of current studies
and the buzz that they generate.
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C4d deposits on erythrocytes
(EC4d): a new biomarker of
antibody-mediated rejection in
kidney transplantation
To the Editor: We would like to add a relevant piece of
information to the elegant review by Cohen et al.1 on C4d
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as a biomarker of rejection in kidney transplantation by
discussing the pathophysiology of C4d deposition on
erythrocytes (EC4d) and its potential value in clinical
transplantation. EC4d was described 40 years ago as the
determinant for the Chido and Rodgers blood groups. EC4d
was recently described as a marker of lupus activity2 and as
being related to alloantibody response in heart3 and lung4
transplantation. We recently showed that EC4d is a
noninvasive biomarker of antibody-mediated rejection in
kidney transplantation.5 EC4d levels paralleled donor-speciﬁc
anti-human leukocyte antibody occurrence, peritubular
capillary C4d staining, and were more predictive of
peritubular capillaritis, with better sensitivity, speciﬁcity,
and positive predictive value compared with peritubular
C4d. Interestingly, we observed that the major factor
determining the amount of C4d deposition is immunoglobu-
lin (Ig)G concentration. We found that C4d deposition on
erythrocytes in vitro can be triggered by changing the physical
conditions of the medium. We hypothesized that IgG
aggregation, owing to high sucrose concentration, initiates
C4d activation in vitro. C3d is another potential covalent
footprint that could be found in tissues and on erythrocytes in
the range of 1–3 log higher because of the C3 ampli-
ﬁcation loop.6 Surprisingly, C3d deposits are not detected or
may be detected at a very lower level than expected on
erythrocytes and in tissues. Another interesting issue is the
higher prevalence of C4d positivity in ABO-incompatible
renal allografts (almost invariably present) when compared
with positive cross-match transplants and recipients with
preformed donor-speciﬁc alloantibodies. The two immuno-
globulin classes are actually different in the two groups.
In ABO-incompatible transplants, natural IgM antibodies
that activate the complement are involved, as against anti-
human leukocyte IgG antibodies in positive cross-match
transplants. IgM antibodies are more efﬁcient in classical
complement pathway activation when compared with IgG
antibodies.7 IgM antibodies can also lead to C4d depo-
sition by the lectin pathway,8 thereby explaining the
excess C4d deposition in ABO-incompatible kidney trans-
plantation.
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Targeting K–ATP channel in
diabetic nephropathy: opening or
closing?
To the Editor: The effects of oral antidiabetic agents on
diabetic nephropathy have been thought to be due to their
ability to control blood glucose levels, and few studies have
examined whether these agents may also have direct effects on
the kidney.
Hung et al.1 have now examined the effect of three
different oral antidiabetic agents on renal outcome indepen-
dently of blood glucose control. The authors concluded that
sulfonylurea agents might not be desirable compared with
other treatments because of unfavorable renal effects.
However, these investigators did not give a speciﬁc reason
for why this is the case.
Sulfonylurea agents bind to its receptor (SUR), which is a
subunit of the ATP-dependent K channel. In pancreatic b-cells
the binding of sulfonylurea to SUR causes the K–ATP channel
to close, resulting in insulin secretion. In turn, another
subtype ‘SUR2’ is located in the kidney. In particular, SUR2
is expressed in mesangial cells, tubular epithelial cells, and
podocytes.2 Hence, it is conceivable that sulfonylurea could
act in the kidney.
In contrast to closing the K–ATP channel with sulfonyl-
urea, opening the channel is likely renoprotective. In fact,
iptakalim, a selective K–ATP channel opener, was found to
lower systemic blood pressure in association with endothelial
protection and lowering uric acid. Likewise, several research-
ers including our group demonstrated that opening of the
K–ATP channel with nicorandil contributes, along with its
ability to donate nitric oxide, to blocking the experimental
renal injury, including advanced diabetic nephropathy.2
Presumably, these lines of evidence could account for its
unfavorable effects in the kidney of type 2 diabetic subjects.
However, we should be aware that the effects of sulfo-
nylurea may be more complicated. Cortes’s3 research group
demonstrated that glibenclamide blocks high glucose–induced
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